ELVN Stock: Price, Earnings History and SEC Filings
Enliven Therapeutics, Inc. (ELVN) last traded at $44.25, down 1.84% on the latest session and down 3.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.49 against an analyst estimate of $-0.38, a miss of 28.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ELVN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-0.49 | $-0.38 | -28.95% |
| Mar 2026 | May 7, 2026 | $-0.38 | $-0.44 | +13.64% |
| Dec 2025 | Mar 3, 2026 | $-0.48 | $-0.42 | -14.29% |
| Sep 2025 | Nov 12, 2025 | $-0.32 | $-0.43 | +25.58% |
ELVN beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How ELVN reacts to earnings
Across its last 8 earnings releases, ELVN moved 3.0% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | After close | +0.95% |
| 2026-05-07 | After close | +1.14% |
| 2026-03-03 | After close | +4.28% |
| 2025-11-12 | After close | -0.15% |
| 2025-08-13 | After close | -1.08% |
| 2025-05-14 | After close | -10.41% |
| 2025-03-13 | After close | +2.22% |
| 2024-11-13 | After close | -3.41% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ELVN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$104M | – | – | $-1.83 |
| 2024 | – | -$89M | – | – | $-1.89 |
| 2023 | – | -$72M | – | – | $-2.01 |
| 2022 | – | -$38M | – | – | $-12.05 |
| 2021 | – | -$51M | – | – | $-2.37 |
| 2020 | – | -$41M | – | – | – |
| 2019 | – | -$23M | – | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ELVN
- 8-K · Oct 14, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 12, 2026Material agreement, Regulation FD disclosure, Financial statements and exhibits
- 424B5 · Jun 12, 2026
- 424B5 · Jun 11, 2026
- 8-K · Jun 11, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jun 10, 2026Bylaw change, Shareholder vote, Financial statements and exhibits
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
Insider filing activity
ELVN insiders filed 9 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ELVN news
No recent headlines found. The live terminal has the full news feed.
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. (ELVN) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.